JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruiz, M.
Right arrow Articles by Glover, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruiz, M.
Right arrow Articles by Glover, D. K.
Journal of Nuclear Medicine Vol. 43 No. 5 664-670
© 2002 by Society of Nuclear Medicine


Basic Science Investigations

Arbutamine Stress Perfusion Imaging in Dogs with Critical Coronary Artery Stenoses: 99mTc-Sestamibi Versus 201Tl

Mirta Ruiz, MD, Kazuya Takehana, MD, Frank D. Petruzella, BA, Denny D. Watson, PhD, George A. Beller, MD and David K. Glover, ME

Experimental Cardiology Laboratory, Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia

Having previously shown that dobutamine reduces 99mTc-methoxyisobutylisonitrile (sestamibi [MIBI]) uptake in normal myocardium by elevating intracellular calcium, we hypothesized that arbutamine, which has less inotropic effect than dobutamine, might cause less reduction in MIBI uptake, thereby improving defect contrast. In this study using a canine model, we compared the effects of arbutamine stress on myocardial blood flow, myocardial MIBI uptake, and systolic thickening in the presence of a coronary artery stenosis. Methods: Arbutamine was infused (0.5–250 ng/kg/min) in 8 open-chest dogs with critical coronary stenoses that abolished flow reserve. At the time of peak arbutamine effect, MIBI (296 MBq), 201Tl (27.75 MBq), and microspheres were coinjected. The dogs were killed 5 min later, and myocardial tracer activities and flow were quantified by well counting. Ex vivo imaging of heart slices was also performed. Results: Arbutamine increased mean heart rate, peak positive left ventricular pressure and its first time-derivative, and normal-zone myocardial thickening. Stenotic zone flow and thickening did not increase during arbutamine infusion. MIBI uptake versus flow was significantly lower than 201Tl uptake at the same flow values. By imaging, defect magnitude (stenotic/normal) was greater for 201Tl than MIBI (0.56 vs. 0.57; P < 0.001). Conclusion: In the presence of coronary stenoses that abolished regional flow reserve, myocardial uptake of MIBI, compared with 201Tl, significantly underestimated the arbutamine-induced flow heterogeneity. The attenuation of MIBI uptake and diminished defect contrast during arbutamine stress were comparable with those previously reported for dobutamine stress.

Key Words: arbutamine • 99mTc-sestamibi • coronary disease







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.